Shares of Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) traded down 11.1% during trading on Friday . The stock traded as low as $1.60 and last traded at $1.60. 101 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 9,638 shares. The stock had previously closed at $1.80.
Silence Therapeutics Price Performance
The business has a 50-day simple moving average of $1.61 and a two-hundred day simple moving average of $1.49.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Featured Stories
- Five stocks we like better than Silence Therapeutics
- 3 Monster Growth Stocks to Buy Now
- AI Demand Is Coming—Is Microchip Technology Ready?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Why Investors Have Flocked to 2 Unorthodox ETFs This Month
- What Are the FAANG Stocks and Are They Good Investments?
- Rivian’s Chart Says Go, But Some Analysts Still Say No
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
